A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

被引：0
|
作者：
Yiyun Wang
Yingying Yang
Ruimin Hong
Houli Zhao
Guoqing Wei
Wenjun Wu
Huijun Xu
Jiazhen Cui
Yanlei Zhang
Alex H. Chang
Yongxian Hu
He Huang
机构：
[1] Zhejiang University School of Medicine,Bone Marrow Transplantation Center, The First Affiliated Hospital
[2] Zhejiang University,Institute of Hematology
[3] Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Zhejiang Laboratory for Systems & Precision Medicine
[4] Zhejiang University Medical Center,undefined
[5] Shanghai YaKe Biotechnology Ltd,undefined
来源：
Blood Cancer Journal | / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
    Schultz, Liora M.
    Muffly, Lori S.
    Spiegel, Jay Y.
    Ramakrishna, Sneha
    Hossain, Nasheed
    Baggott, Christina
    Sahaf, Bita
    Patel, Shabnum
    Craig, Juliana
    Yoon, Jenny
    Kadapakkam, Meena
    Majzner, Robbie G.
    Frank, Matthew J.
    Erickson, Courtney
    Marcy, Anne Cunniffe
    Fujimoto, Michelle
    Bhatia, Neehar
    Meyer, Everett H.
    Kong, Katherine A.
    Egeler, Emily
    Mavroukakis, Sharon
    Qin, Haiying
    Fry, Terry J.
    Feldman, Steven A.
    Miklos, David B.
    Mackall, Crystal L.
    Davis, Kara L.
    BLOOD, 2019, 134
  • [42] CD19/CD22 Dual-Targeted CAR-TTherapy Active in Relapsed/Refractory DLBCL
    不详
    ONCOLOGIST, 2020, 25 : S12 - S13
  • [43] Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
    Liang, Zuyu
    Cui, Jiazhen
    Chang, Alex Hongsheng
    Yu, Jian
    Hu, Yongxian
    Huang, He
    REGENERATIVE THERAPY, 2020, 15 : 281 - 284
  • [44] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Shaun Cordoba
    Shimobi Onuoha
    Simon Thomas
    Daniela Soriano Pignataro
    Rachael Hough
    Sara Ghorashian
    Ajay Vora
    Denise Bonney
    Paul Veys
    Kanchan Rao
    Giovanna Lucchini
    Robert Chiesa
    Jan Chu
    Liz Clark
    Mei Mei Fung
    Koval Smith
    Carlotta Peticone
    Muhammad Al-Hajj
    Vania Baldan
    Mathieu Ferrari
    Saket Srivastava
    Ram Jha
    Frederick Arce Vargas
    Kevin Duffy
    William Day
    Paul Virgo
    Lucy Wheeler
    Jeremy Hancock
    Farzin Farzaneh
    Sabine Domning
    Yiyun Zhang
    Nushmia Z. Khokhar
    Vijay G. R. Peddareddigari
    Robert Wynn
    Martin Pule
    Persis J. Amrolia
    Nature Medicine, 2021, 27 : 1797 - 1805
  • [45] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Cordoba, Shaun
    Onuoha, Shimobi
    Thomas, Simon
    Pignataro, Daniela Soriano
    Hough, Rachael
    Ghorashian, Sara
    Vora, Ajay
    Bonney, Denise
    Veys, Paul
    Rao, Kanchan
    Lucchini, Giovanna
    Chiesa, Robert
    Chu, Jan
    Clark, Liz
    Fung, Mei Mei
    Smith, Koval
    Peticone, Carlotta
    Al-Hajj, Muhammad
    Baldan, Vania
    Ferrari, Mathieu
    Srivastava, Saket
    Jha, Ram
    Vargas, Frederick Arce
    Duffy, Kevin
    Day, William
    Virgo, Paul
    Wheeler, Lucy
    Hancock, Jeremy
    Farzaneh, Farzin
    Domning, Sabine
    Zhang, Yiyun
    Khokhar, Nushmia Z.
    Peddareddigari, Vijay G. R.
    Wynn, Robert
    Pule, Martin
    Amrolia, Persis J.
    NATURE MEDICINE, 2021, 27 (10) : 1797 - +
  • [46] Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis
    Nguyen, Thi Thuy
    Thanh Nhu, Nguyen
    Chen, Chia-Ling
    Lin, Chiou-Feng
    CANCER MEDICINE, 2023, 12 (18): : 18767 - 18785
  • [47] Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy
    Ahmed, Nausheen
    Caimi, Paolo
    Reese, Jane S.
    Otegbeye, Folashade
    Patel, Seema
    Schneider, Dina
    Boughan, Kirsten M.
    Cooper, Brenda
    Gallogly, Molly
    Kruger, Winfred
    Worden, Andrew
    Kadan, Michael
    Lopes, Filipa Blasco Tavares Pereira
    Sharma, Ashish
    Malek, Ehsan
    Metheny, Leland
    Tomlinson, Benjamin
    Wald, David
    Sekaly, Rafick-Pierre
    Orentas, Rimas
    Dropulic, Boro
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S275 - S276
  • [48] CD19 Directed Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis
    Anagnostou, Theodora
    Bin Riaz, Irbaz
    Hashmi, Shahrukh K.
    Murad, Mohammad Hassan
    Kenderian, Saad S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [49] Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy
    Qiu, Songlin
    Pan, Ye
    Shi, Shenyan
    Omotoyosi, Fapohunda Funmilayo
    Chen, Keping
    Guo, Zhigang
    Lu, Peng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (05) : 335 - 341
  • [50] Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
    Horvei, Paulina
    Sakemura, Reona
    Cox, Michelle J.
    Roman, Claudia Manriquez
    Schick, Kendall J.
    Ruff, Michael W.
    Hefazi, Mehrdad
    Tapper, Erin E.
    Hansen, Michael J.
    Schanzer, Juergen
    Endell, Jan
    Kay, Neil E.
    Nowakowski, Grzegorz S.
    Kenderian, Saad S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S223 - S224
12345